A Phase3 Study to Evaluate the Efficacy and Safety of MEDI3250 in Healthy Japanese Children Age 7 Years Through 18 Years
NCT02269475
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
1369
Enrollment
INDUSTRY
Sponsor class
Conditions
Healthy Japanese Children Age 7 Years Through 18 Years
Interventions
DRUG:
MEDI3250
DRUG:
Placebo
Sponsor
AstraZeneca